{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:12:46Z","timestamp":1791353566589,"version":"4.3.1"},"reference-count":120,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cancer immunotherapy has now entered clinical practice and has reshaped the standard of care for many cancer patients. With these new strategies, specific toxicities have emerged, and renal side effects have been described. In this review, we will describe the causes of acute kidney injury in CAR T cell, immune checkpoint inhibitors and other cancer immuno-therapy recipients. CAR T cell therapy and bispecific T cell engaging antibodies can lead to acute kidney injury as a consequence of cytokine release syndrome, tumor lysis syndrome, sepsis or specific CAR T cell infiltration. Immune checkpoint blockade most often results in acute tubular interstitial nephritis, but glomerular diseases have also been described. Although the pathophysiology remains mostly elusive, we will describe the mechanisms of renal damage in these contexts, its prognosis and treatment. As the place of immunotherapy in the anti-cancer armamentarium is exponentially increasing, close collaboration between nephrologists and oncologists is of utmost importance to provide the best standard of care for these patients.<\/jats:p>","DOI":"10.3390\/cells11243991","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T03:36:09Z","timestamp":1670816169000},"page":"3991","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Acute Kidney Injury in Cancer Immunotherapy Recipients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-8966","authenticated-orcid":false,"given":"Adrien","family":"Joseph","sequence":"first","affiliation":[{"name":"Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lafarge","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the Knowledge of Sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models","volume":"8","author":"Decker","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute Kidney Injury in Patients with Cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41581-021-00405-7","article-title":"Kidney injury and disease in patients with haematological malignancies","volume":"17","author":"Bridoux","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1093\/ndt\/gfy051","article-title":"Acute kidney injury in critically ill patients with solid tumours","volume":"33","author":"Kemlin","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: Continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","first-page":"669","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21702","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Schellongowski","year":"2022","journal-title":"CA Cancer, J. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.bbmt.2018.12.307","article-title":"Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia","volume":"25","author":"Myers","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s004670050760","article-title":"Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats","volume":"14","author":"Garin","year":"2000","journal-title":"Pediatr. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease","volume":"15","author":"Fakhouri","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2014.10.012","article-title":"Acute kidney injury in adults with hemophagocytic lymphohistiocytosis","volume":"65","author":"Aulagnon","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.ki.5000352","article-title":"Nephrotic syndrome associated with hemophagocytic syndrome","volume":"69","author":"Thaunat","year":"2006","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00134-019-05768-x","article-title":"Understanding tumor lysis syndrome","volume":"45","author":"Zafrani","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1681\/ASN.2021070997","article-title":"Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms","volume":"33","author":"Arnaud","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2021.07.012","article-title":"Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report","volume":"79","author":"Camus","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.aat5031","article-title":"Spatiotemporal immune zonation of the human kidney","volume":"365","author":"Stewart","year":"2019","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MCC.0000000000000978","article-title":"Severe infections in recipients of cancer immunotherapy: What intensivists need to know","volume":"28","author":"Joseph","year":"2022","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.kint.2019.05.026","article-title":"Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment","volume":"96","author":"Peerapornratana","year":"2019","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41581-021-00489-1","article-title":"Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury","volume":"18","author":"Molema","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: A cancer entity with a shared sensitivity to the PD-1\/PD-L1 pathway blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients with Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1927313","DOI":"10.1080\/2162402X.2021.1927313","article-title":"Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: A 10-year single-institution analysis","volume":"10","author":"Abdelrahim","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin. Kidney J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of Acute Interstitial Nephritis with Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmii.2019.10.006","article-title":"Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury","volume":"54","author":"Xu","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"574271","DOI":"10.3389\/fimmu.2020.574271","article-title":"The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient with Malignancy","volume":"16","author":"Boils","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor Regression and Allograft Rejection after Administration of Anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.immuni.2010.11.024","article-title":"An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness","volume":"33","author":"Procaccini","year":"2010","journal-title":"Immunity"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-016-0916-7","article-title":"mTOR inhibitors effects on regulatory T cells and on dendritic cells","volume":"14","author":"Stallone","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results","volume":"36","author":"Dantal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: Systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.34067\/KID.0001192019","article-title":"Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO","volume":"1","author":"Eijgelsheim","year":"2020","journal-title":"Kidney360"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.34067\/KID.0000132020","article-title":"Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON","volume":"1","author":"Gutgarts","year":"2020","journal-title":"Kidney360"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"166","DOI":"10.34067\/KID.0001072019","article-title":"Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary","volume":"1","author":"Perazella","year":"2020","journal-title":"Kidney360"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e001198","DOI":"10.1136\/jitc-2020-001198","article-title":"Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma","volume":"8","author":"Patel","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: Promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e004421","DOI":"10.1136\/jitc-2021-004421","article-title":"Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy","volume":"10","author":"Baker","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal Vasculitis and Pauci-immune Glomerulonephritis Associated with Immune Checkpoint Inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies-BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"626616","DOI":"10.3389\/fimmu.2021.626616","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","article-title":"Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab","volume":"16","author":"Wilke","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013A current perspective","volume":"11","author":"Glickman","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: A review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: Recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: Incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"Lumbreras","year":"2014","journal-title":"Medicine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3109\/23744235.2015.1055794","article-title":"Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: A case series of 22 patients","volume":"47","author":"Pommier","year":"2015","journal-title":"Infect. Dis."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ndt\/gfh688","article-title":"Acute renal failure following intravesical bacille Calmette-Gu\u00e9rin chemotherapy for superficial carcinoma of the bladder","volume":"20","author":"Fry","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/ndt\/gfk071","article-title":"Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG","volume":"21","author":"Kennedy","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.medmal.2020.09.009","article-title":"Intravesical BCG instillation as a possible cause of acute and chronic kidney injury","volume":"51","author":"Tamzali","year":"2021","journal-title":"Infect. Dis. Now"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000168368","article-title":"Renal complications of intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"11","author":"Modesto","year":"1991","journal-title":"Am. J. Nephrol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Mohammed, A., and Arastu, Z. (2017). Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer. BMC Urol., 17.","DOI":"10.1186\/s12894-017-0304-5"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/08860220601098961","article-title":"Nephrotic syndrome as a complication of intravesical BCG treatment of transitional cell carcinoma of urinary bladder","volume":"29","author":"Singh","year":"2007","journal-title":"Ren. Fail"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2169\/internalmedicine.56.7494","article-title":"Henoch Sch\u00f6nlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy","volume":"56","author":"Tsukada","year":"2017","journal-title":"Intern Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e199249","DOI":"10.1001\/jamanetworkopen.2019.9249","article-title":"Adverse Events Associated with the Use of Sipuleucel-T Reported to the US Food and Drug Administration\u2019s Adverse Event Reporting System, 2010\u20132017","volume":"2","author":"Dores","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Kimbrough","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: Leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/3991\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:37Z","timestamp":1760146657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/24\/3991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":120,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cells11243991"],"URL":"https:\/\/doi.org\/10.3390\/cells11243991","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]}}}